Group items tagged

For Dr. John Evans, growing a strong biotechnology industry is much the same: cities must provide a nurturing environment where science and business can thrive together.

That's why Evans, former president of the University of Toronto and current chairman of Torstar Corp., is spearheading the $345-million Medical and Related Science initiative, or MaRS--a petri dish of sorts for commercializing science research. "A lot of intellectual property is being commercialized outside Canada," says Evans. "I think we've been slow in realizing just how important technology developments are to the economic future of the country. MaRS is an attempt to give this a kick into a higher gear." The centrepiece of the MaRS plan, which will officially launch May 12, is a 1.3-million-square-foot, five-building complex in downtown Toronto that will provide office and lab space for small and medium-size companies and incubators, including the not-for-profit Toronto Biotechnology Commercialization Centre. While Evans is reluctant to limit its scope, MaRS will generally focus on health-related technologies, from new drugs and genetic treatments to medical devices and imaging software. Branded a "convergence centre," it will also house a careful mix of support services: intellectual property lawyers, accountants, marketing experts, government funding organizations and venture capital financiers. Plus, start-ups will have access to all the latest equipment on site. For instance, MaRS is in talks with MDS Sciex to supply mass spectrometers, used in proteomics research.

But MaRS will be more than just a New Economy real estate development. Evans's intention is to funnel tenants' rent money into services--such as entrepreneurship seminars and angel-matching programs--that MaRS will offer to the broader biotech community. That's why MaRS's location is key: the centre will be built in the heart of what Toronto has dubbed the "Discovery District," a two-square-kilometre chunk of the downtown core, encompassing U of T and four major hospitals. From there, MaRS hopes to act as a network hub across Ontario, with links to research-intensive universities. "None of them," says Evans, "have the critical mass to put it all together on their own."

Peter Evans, adviser to the Toronto technology organization MaRs, believes Canada's economy is at a crossroads, as critical to job growth as the Industrial Revolution was at the turn of the last century.

We don’t know for sure,” said Dr. John Evans, chair of the board of directors at MARS (Medical and Related Sciences) Discovery District in Toronto, and vicechair of Mississauga, Ont.-based NPSAllelix Biopharmaceuticals, one of the pioneers of biotech in Canada. “But we believe that if you could ‘type’ the patient processes of how he/she handles a drug, you could peel off those people who would be particularly sensitive to a drug. Then you could find a sub-population where the drug is safe and highly effective.” Evans used the arthritis drug Vioxx as an example. It helped millions of people battle painful inflammation, but was pulled from the market recently because of potential cardiac side effects in some people. “If the drug company could have predicted which patients would have complications from Vioxx treatment — through some genetic profiling — then a very powerful and effective drug could have been preserved,” Evans said. His company, NPS-Allelix Bio-pharmaceuticals, has been developing a product since 1989 that will be launched later this year. The drug secretes a parathyroid hormone for treating osteoporosis.

It builds up bone matrix and helps build bone, rather than just delay bone loss as other drugs do.

BNN interviews Gordon Nixon, incoming chair, MaRS Discovery District; John Evans, outgoing chair, MaRS Discovery District.

"This investment underscores the government's recognition that Ontario must continue to invest in its strong life sciences cluster. Now more than ever, innovative research and development is a key driver, reshaping the knowledge economy and creating prosperity for all Ontarians." Dr. John Evans, Chair, MaRS Discovery District

Ontario is launching a new fund to attract and retain world-leading genomics researchers in the province. The CAD$100-million (£56.1-million) Global Leadership Round in Genomics and Life Sciences will support globally-significant, collaborative research projects that are headquartered in Ontario, Canada. This fund will create high-skilled jobs in research and technology, and brings Ontario`s commitment to funding science since 2003 to a historic high of $1.4 billion (£785 million).

This is Toronto's research district, a maze of concrete and glass where the finest minds collaborate, turning the city into a global centre of biomedical discovery.

Nine research institutes employing 5,000 university faculty members, 2,000 graduate students and 1,100 postdoctoral and clinical fellows lie within a 20-minute walk of each other. This biomedical cluster at the heart of Toronto is one of the largest on the continent, and is one of the 10 largest in the world.

Tom Hudson from Montreal; cell biologist Ben Neel from Boston; and stem-cell biologist Gordon Keller, who came to Toronto in 2006, just months after New York magazine named him one of the scientists that city could not afford to lose. Toronto is also home to Tak Mak, who discovered the "key to the immune system" T-cell receptor, and John Dick, who discovered the first cancer stem cell in 1994 and last year grew a human cancer in a lab mouse for the first time.

non-profit, charitable and voluntary organizations that provide programs and services

a troubling picture of the financial and regulatory burdens facing the third sector

The Board of Directors of the Ontario Institute for Cancer Research (OICR) has appointed Dr. Calvin Stiller as the Chair of the Board.

He succeeds Dr. John Evans, who was the first Chair and who will continue to serve as a board member.

Dr. Stiller co-founded the MaRS Centre in Toronto

MARS DISOVERY DISTRICT has appointed businessman and philanthropist Richard Ivey to its board of directors.

"Richard Ivey has a strong track record of community involvement and commitment to research and innovation, most recently through his continuing role as chair of the Canadian Institute for Advanced Research," said John Evans, founding chair of the board at MaRS. "His integrity and dedication to building a strong foundation for Canada's innovation economy will be of tremendous benefit to MaRS"

MaRS is a Toronto non-profit centre linking science, technology and social entrepreneurs with business skills and capital to stimulate innovation and the creation of successful Canadian companies.